Cogent Biosciences, Inc.
COGT
Classifica tra le azioni
#3275
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$31.01
Capitalizzazione di mercato
$5.38B
Variazione (1 giorno)
3.33%
Variazione (1 anno)
91.17%
Paese
US
Scambia Cogent Biosciences, Inc. (COGT)
Categoria
Healthcare
Rapporto P/B per Cogent Biosciences, Inc. (COGT)
Rapporto P/B al October 2026 TTM: 9.04
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Cogent Biosciences, Inc., il rapporto P/B attuale (TTM) è 9.04. Alla fine del 2023, era pari a 1.82.
Storico del rapporto P/B per Cogent Biosciences, Inc. da 2015 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 9.04 | 186.14% |
| 2024 | 3.16 | 73.98% |
| 2023 | 1.82 | -31.58% |
| 2022 | 2.66 | 71.14% |
| 2021 | 1.55 | 192.57% |
| 2020 | 0.53 | -23.25% |
| 2019 | 0.69 | -62.01% |
| 2018 | 1.82 | -84.34% |
| 2017 | 11.61 | 133.80% |
| 2016 | 4.97 | 32.70% |
| 2015 | 3.74 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | -30.87% |
US
|
|
| 13.2547 | 46.59% |
US
|
|
| 4.208 | -53.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.62% |
NL
|
